Results 181 to 190 of about 49,037 (222)
Some of the next articles are maybe not open access.

Rifampin Drug Interactions

Archives of Internal Medicine, 1984
Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-
A M, Baciewicz, T H, Self
openaire   +2 more sources

Corneal Penetration of Rifampin

American Journal of Ophthalmology, 1977
We tested the corneal penetration of rifampin in four vehicles: dimethylsulfoxide, polyethylene glycol, an ocular lubricant, and as rifampin ointment. We measured drug concentrations in the aqueous humor in rabbits after topical instillation of 1 and 2.5% rifampin according to two dosage schedules.
M F, Feldman, R A, Moses
openaire   +2 more sources

Rifampin

Journal of Urology, 1982
B, Farr, G L, Mandell
openaire   +2 more sources

Verapamil-Rifampin Interaction

Drug Intelligence & Clinical Pharmacy, 1985
A case of verapamil-rifampin interaction is presented in a patient receiving verapamil for supraventricular tachycardia (SVT) and rifampin for pulmonary tuberculosis. The patient experienced recurrent symptomatic SVT, despite receiving verapamil 480 mg po q6h. Serum verapamil concentrations were determined to be extremely low.
openaire   +2 more sources

Rifampin in dermatology

Clinics in Dermatology, 2003
Nikolai, Tsankov, Irena, Angelova
openaire   +3 more sources

Rifampin in the Treatment of Leprosy

Clinical Infectious Diseases, 1983
The minimal inhibitory concentration of rifampin for Mycobacterium leprae is less than 1 microgram/ml. Therapy with rifampin has proved efficacious both in mice experimentally infected with M. leprae and in humans with leprosy. Rifampin kills M. leprae more rapidly than do other antileprosy drugs currently available. Consequently, M.
openaire   +2 more sources

Home - About - Disclaimer - Privacy